On September 22, AKESO declined 3.07% in regular trading, trading at approximately 96.5 HKD/share, with turnover of approximately 174 million HKD. The retreat comes after the stock surged over 8.9% in the prior session amid a sector-wide rally in innovative drug stocks.

The previous session's spike was driven by two catalysts: reports that the US may ease licensing cooperation restrictions for pharmaceutical companies, boosting sentiment around cross-border biotech deal-making, and sustained momentum from the World Conference on Lung Cancer where AKESO's ivonescimab (AK112) HARMONi-2 study reported statistically significant overall survival results. Data showed median OS of 30.8 months for the ivonescimab arm versus 22.6 months for pembrolizumab, with a hazard ratio of 0.73. Multiple investment banks including CITIC, Jefferies, Citi, and J.P. Morgan maintained buy or outperform ratings, with target prices ranging from 125 to 226 HKD.

Following concentrated release of positive catalysts and rapid share price appreciation, today's decline reflects partial profit-taking after the sharp short-term gains.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)